After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight
Executive Summary
Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13
You may also be interested in...
Lipitor Adds Claims For High-Dose Use From TNT, IDEAL – But Label Is Mixed
Lipitor (atorvastatin) has gained approval for five new indications based on the Treating to New Targets and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering studies, but the updated labeling includes mixed statements about the benefits of treatment with higher doses of atorvastatin
Lipitor Adds Claims For High-Dose Use From TNT, IDEAL – But Label Is Mixed
Lipitor (atorvastatin) has gained approval for five new indications based on the Treating to New Targets and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering studies, but the updated labeling includes mixed statements about the benefits of treatment with higher doses of atorvastatin
CVS/Caremark May Have Less Formulary Adherence, Express Scripts Says
CVS/Caremark's intention to be "agnostic" to whether prescriptions are filled by mail or retail could adversely affect the proposed entity's ability to manage members' formulary adherence, Express Scripts VP-Investor Relations David Myers suggested